Current treatment options for HR+, HER2‐negative advanced breast cancer (ABC) include endocrine therapies (eg, tamoxifen and aromatase inhibitors), targeted therapies (eg, cyclin‐dependent kinase 4/6 [CDK4/6] inhibitors), and chemotherapy.3, 4. This evidence concerns the gene ERBB2 and breast cancer.